Copyright
©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 21, 2017; 23(23): 4243-4251
Published online Jun 21, 2017. doi: 10.3748/wjg.v23.i23.4243
Published online Jun 21, 2017. doi: 10.3748/wjg.v23.i23.4243
miR-382 functions as a tumor suppressor against esophageal squamous cell carcinoma
Jie Feng, Bo Qi, Ling Guo, Xiu-Feng Wei, Yu-Zhen Liu, Bao-Sheng Zhao, Department of Thoracic Surgery, The First Affiliated Hospital of Xinxiang Medical University, Weihui 453100, Henan Province, China
Ling-Yun Chen, Department of Operating Room, The First Affiliated Hospital of Xinxiang Medical University, Weihui 453100, Henan Province, China
Author contributions: Feng J and Qi B contributed equally to this work; Liu YZ and Zhao BS contributed to conception and design; Feng J and Qi B designed methods and performed the majority of experiments; Guo L, Chen LY and Wei XF contributed to revision of the manuscript for intellectual content; Liu YZ interpreted the results and wrote the paper.
Supported by Key Technologies R&D Program of Science and Technology Commission of Henan Province , No. 152102310110 to Zhao BS ; and Key Science and Technique Fund of Xinxiang , No. ZG15018 to Zhao BS .
Institutional review board statement: This study was reviewed and approved by the First Affiliated Hospital of Xinxiang Medical University Institutional Review Board.
Conflict-of-interest statement: The authors declared that no conflict of interest exists in this study.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Bao-Sheng Zhao, MD, Professor of Surgery, Chief, Department of Thoracic Surgery, The First Affiliated Hospital of Xinxiang Medical University, 88 Jiankang Road, Weihui 453100, Henan Province, China. zhaobscn@126.com
Telephone: +86-373-4404718 Fax: +86-373-4402573
Received: January 1, 2017
Peer-review started: January 4, 2017
First decision: February 9, 2017
Revised: March 14, 2017
Accepted: March 31, 2017
Article in press: March 31, 2017
Published online: June 21, 2017
Peer-review started: January 4, 2017
First decision: February 9, 2017
Revised: March 14, 2017
Accepted: March 31, 2017
Article in press: March 31, 2017
Published online: June 21, 2017
Core Tip
Core tip: Our previous study revealed that miR-382 was significantly down-regulated in esophageal squamous cell carcinoma (ESCC) patients with short-term motility, implying that miR-382 may display antitumor function in ESCC development and metastasis. We present here that miR-382 functions as a tumor suppressor by inhibiting proliferation, migration, invasion and epithelial-mesenchymal transition, in addition to inducing cell cycle arrest, apoptosis and autophagy in Eca109 cells. Inhibitory influence on protein translation mediated by mTOR/4E-BP1 signaling might be involved in the antitumor activity of miR-382 against ESCC. Thus, manipulation of miR-382 level can be a potentially therapeutic intervention for ESCC.